Abstract 3589: Validation of the role of circulating tumor DNA (ctDNA) in tracking mechanisms of resistance to anti-EGFR monoclonal antibodies (AE-mABs): preliminary results of the PROSPECT-C prospective trial

2015 ◽  
Author(s):  
Khurum Khan ◽  
George Vlachogianis ◽  
David Cunningham ◽  
Jens Hahne ◽  
Mahnaz Darvish-Damavandi ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Prospective Trial ◽  
Circulating Tumor Dna ◽  
Mechanisms Of Resistance ◽  
Preliminary Results ◽  
Tumor Dna

Abstract 5235: Circulating tumor DNA as a prognostic marker in colorectal cancer: Preliminary results of a prospective trial

2015 ◽  
Author(s):  
Pierre Laurent-Puig ◽  
Olivier Bouché ◽  
Ralph Niarra ◽  
Pascaline Aucouturier ◽  
Leonor Benhaim ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Marker ◽  
Prospective Trial ◽  
Circulating Tumor Dna ◽  
Preliminary Results ◽  
Tumor Dna

scholarly journals Liquid biopsy in NSCLC: a new challenge in radiation therapy

2021 ◽  
Author(s):  
Annarita Perillo ◽  
Mohamed Vincenzo Agbaje Olufemi ◽  
Jacopo De Robbio ◽  
Rossella Margherita Mancuso ◽  
Anna Roscigno ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Liquid Biopsy ◽  
Residual Disease ◽  
Biological Fluids ◽  
Circulating Tumor Dna ◽  
Minimum Residual ◽  
Nsclc Patients ◽  
Choice Of Therapy ◽  
Tumor Dna

Lung cancer is the most common cancer and the leading cause of cancer mortality worldwide. To date, tissue biopsy has been the gold standard for the diagnosis and the identification of specific molecular mutations, to guide choice of therapy. However, this procedure has several limitations. Liquid biopsy could represent a solution to the intrinsic limits of traditional biopsy. It can detect cancer markers such as circulating tumor DNA or RNA (ctDNA, ctRNA), and circulating tumor cells, in plasma, serum or other biological fluids. This procedure is minimally invasive, reproducible and can be used repeatedly. The main clinical applications of liquid biopsy in non-small cell lung cancer (NSCLC) patients are the early diagnosis, stratification of the risk of relapse, identification of mutations to guide application of targeted therapy and the evaluation of the minimum residual disease. In this review, the current role of liquid biopsy and associated markers in the management of NSCLC patients was analyzed, with emphasis on ctDNA and CTCs, and radiotherapy.

scholarly journals Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC

2020 ◽  
Author(s):  
Julia Roeper ◽  
Sylke Kurz ◽  
Christian Grohé ◽  
Frank Griesinger
Keyword(s):  
Treatment Duration ◽  
Kinase Inhibitors ◽  
Circulating Tumor Dna ◽  
Real World Data ◽  
Patient Attrition ◽  
Egfr Tki ◽  
Tumor Dna ◽  
Egfr Tkis ◽  
Optimal Treatment Strategy

Clinical trial and real-world data in non-small-cell lung cancer indicate that 10–60% of patients that progressed on first- or second-generation EGFR-targeting tyrosine kinase inhibitors (TKI) do not receive systemic second-line therapy. In our article, we discuss efficacy, safety and treatment duration with different EGFR-TKIs and stress the need for delivery of the most efficacious therapy in the first-line. We also provide our perspective on analysis of circulating tumor DNA and the role of EGFR-TKI in combined therapies. Finally, we review new therapeutic options to overcome resistance to EGFR-TKI. We believe that overall treatment duration and access to different medications in subsequent lines of therapy should be considered when planning the optimal treatment strategy.

Sign in / Sign up

Export Citation Format

Share Document